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Background: Abiraterone acetate (AA) is approved by FDA as
second line treatment for patients (pts) with CRPC that
experience disease progression after first line docetaxel
chemotherapy. AA is a potent inhibitor of both 17a-
hydroxylase and 17,20-lyase (CYP17) activity. This inhibition
may produce an increase in the concentrations of steroids
synthesized upstream of the CPY17, with consequent adverse
effects as hypokalemia, fluid retention and hypertension.
Patients and Methods: Since November 2011, 28 pts with
CRPC treated at IRCCS of Candiolo received AA plus
prednisone (5 mg twice daily). Pts had undergone previous
treatment with one or more lines of chemotherapy, in
particular 89.3% of pts (25/28) had been treated with
docetaxel (schedule 75 mg/m2 1/21), 35,7% of pts (10/28)
received two lines of chemotherapy (docetaxel followed by
mitoxantrone), 10.7% of pts (3/28) underwent chemotherapy
with docetaxel with weekly schedule, one patient was treated
with two lines of docetaxel, and one patient with a rechallenge
of docetaxel after previous docetaxel and mitoxantrone
chemotherapies. Twelve patients are still undergoing treatment
with AA. We recorded all grades toxicity (according to NCI-
CTACE v 4.0), with special regard to those related to the
mineralcorticoid excess that may be induced by AA. Results:
All pts included in the study had a good performance status
(ECOG 0-1). Median age was 72.5 years (range 54-79) and
10 pts (35.7%) were older than 75 years. Hypertension was
the most frequent adverse event and occurred in the totality of
pts, though it was not worsened by therapy with AA and only
7 cases (25%) presented grade 3 toxicity. Hypokalemia
occurred in 7.1% of pts (2/28), all cases were grade 1, without
any indication for prompt correction. The incidence of fluid
retention was 14.3% (4/28) and grade 1 or 2 peripheral
oedema accounted for most of these events. There was no
onset of cardiac arrhythmias. Other common toxicities
included back pain (32.1%), fatigue (39.3%), arthralgia
(21.4%) diarrhea (18%), vomiting (7.1%) and nausea (7.1%).
Anemia occurred in 21% of patients and was of grade 3 in one
case. Conclusion: Abiraterone acetate has a very favorable
toxicity profile, with low incidence of grade 3 toxicities and
is a feasible treatment even for patients with hypertension.
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Background: Penile metastasis is a relatively uncommon event
with about 500 cases reported in the literature from 1961 to
the present. The aim of our study was to conduct a systematic
literature review of the past 10 years on this particular subject.
Materials and Methods: We conducted a systematic search in
PubMed (http://www.ncbi.nlm.nih.gov), from January 2003 to
April 2013, including the combination of the following terms:
“penile/penis tumor”, “penis/penile metastasis”, “penile/penis
cancer”, “malignat priapism”, limiting the search to articles in
English. Embase and the Cochrane Library were also searched
for the same keywords. Results: A systematic review identified
63 articles published between January 2003 and April 2013
for a total of 77 patients with an age range between 53 and 92
years and a mean follow-up of 1 year. 20 patients (26%) had
metastasis of bladder origin, 19 (25.1%) prostatic, 15 (19.1%)
colorectal, 7 (9.0%) pulmonary, 3 (3.9%) dermal, 3 (3.9%)
esofagic, 2 (2.6%) renal, 2 (2.6%) secondary to lymphoma, 1
(1.3%) respectively from carcinoma of tongue, jaw, thyroid
gland, seminal vesicles, glomangiosarcoma, leukemia myeloid
lineage. In 4 cases (5.2%) penile metastasis was synchronous
with the primary tumor. In the remaining 73, the average time
between the onset of the primary tumor and the penile
metastasis was 41 months (range: 4-60). In 35 patients
(45.5%) metastasis was manifested as painful nodule in 31
(40.3%) with priapism, in 7 (9.1%) as a lump indolent, in 3
(3.8%) with hematuria, and 1 (1.3%) with ulceration. In
agreement with Kendi et al. (Urol Nephrol, 2006), MRI
proved to be the best diagnostic tool/stadiante. The primary
therapeutic approach for the local control of the disease, has
been surgical in 40 cases (51.9%), hormonal in 27 cases
(35.1%), radiotherapy in 5 cases (6.5%) and chemotherapy in
5 (6.5%). The median survival after the diagnosis of penile
secondariness was 10 months (range: 6-18 months).
Discussion: Secondary lesions of the penis are relatively rare
with a high prevalence of malignancy of bladder origin,
prostate and colon/rectum. In agreement with Chaux et al. (Int
J Surg Pathol 2011), penile metastasis is justified as
genitourinary and colon/rectal cancers. No therapy was
significantly higher from the prognostic point of view and the
choice of approach should be considered by evaluating the
performance status of the patient and the local extension of
the lesion and systemic. Conclusion: The small number of
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cases, the poor prognosis and lack of targeted therapeutic
choices impose a registration of cases and a constant review
of the literature in order to identify shared and effective
therapeutic lines. 
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Background: Renal cell carcinoma (RCC) is the most common
primary neoplasm of the kidney, accounting for 3-4% of all
adult malignancies; about 25% of patients is found with
metastatic disease at the time of diagnosis, while another 30%
will develop distant metastases following the surgical
treatment of a localized primary. The most common sites of
metastases from RCC are lungs, lymph nodes, bone, adrenals,
liver and brain, even though rarer metastatic sites are relatively
common, as compared to other malignancies; according to the
literature, metastases to the skin are observed in only 6% of
all RCC cases. Materials and Methods: We reviewed our data
base of 879 consecutive RCC patients evaluated at our Center
between 2004 and 2013 (data cut-off at 31-12-2013), isolating
33 patients with skin metastases, thus confirming the
prevalence reported in the literature (3.8% in our series).
Results: Of the 33 patients with skin metastases collected, the
vast majority (i.e., 30 patients, 90.9%) developed
metachronous skin metastases, with a median time from first
RCC diagnosis to the development of skin metastases of 25.5
months (mean: 48.3, range: 1-272); only 3 patients (9.1%) had
skin metastases that were synchronous to the primary. The
most common sites of skin metastasis were the trunk (14
cases, 42.4%), the head (13 cases, 33.3%), the limbs (7 cases,
21.2%), the neck (1 case, 3%), the fingers (1 case, 3%) and
the gluteus (1 case, 3%); 54% of the patients had thus more
than one site of skin metastases. As far as the morphology of
the lesions, the vast majority of patients had either nodular or
fungoid lesions, with two patients only presenting with
diffuse, shell-like, lesions. As far as the histology of the
primary, a classical clear cell histology was evidenced in 28
cases (84.8%), while 2 other patients showed a papillary or a
prevalent sarcomatoid histology, respectively; as far as the
Fuhrman’s grade of the primary, it was G3 or 4 in 17 cases
(51.5% of the available graded tumors). In 13 cases (39.4%) a
skin biopsy was performed to confirm the metastatic nature of
the skin lesion; in the remaining cases, the diagnosis was
clinical, mainly driven by the progressive growth of the lesions
and by their high vascularization; notably, no cases of
discrepancy between the histology and the grading of the
primary and those of the skin metastases were evidenced.
One-, 3- and 5-year mortality rates in our patients with skin
metastases were 78.8%, 90.9% and 96.9%, respectively, while
median overall survival (calculated from the time of the
development of the first skin metastases to death) was 5
months (mean: 12.9±24.2 SD, range: 1-128). Discussion and
Conclusion: In Conclusion, skin metastases from RCC
account for about 3% of all metastatic sites, are usually
metachronous and related to a more aggressive tumor
phenotype (at least in terms of grading), and are endowed by
a dismailing poor prognosis. 
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Background: Based on available information urothelial cancer
patients with metastases would benefit from surgery. However,
heterogeneity of surgery, treatment, and disease characteristics,
as well as the limited sample size hamper the level of
evidence. We aimed to analyze the contribution of post-
chemotherapy (CT) lymphadenectomy just on survival
outcomes in patients of our center. Patients and Methods:
Between 1986 and 2012, 157 patients with locally advanced
or metastatic urothelial cancer received first-line combination
of methotrexate, vinblastine, doxorubicin, and cisplatin
(MVAC). Of them, only patients experiencing at least a stable
disease of subdiaphragmatic nodal disease/local recurrence
were selected. For the sake of parsimony, the prognostic effect
of singly taken covariates (surgery of tumor primary, site of
nodal disease, extent of nodal sites [single vs. multiple]) upon
survival was investigated using Cox proportional hazard
regression models, with and without adjustment by treatment
group (post-CT surgery vs. observation). Results: 59 patients
were identified, 31 (52.5%) had regional nodes and 28
(47.5%) had metastatic disease. 42 (71.2%) had multiple nodal
sites, 15 pts (25.4%) had an upper tract tumor primary, 24
(40.7%) had received major surgery. Twenty-eight pts
underwent post-chemotherapy pelvic (N=14) or retroperitoneal
lymphadenectomy (N=14) after achieving a complete response
(CR, N=7) or a partial response-stable disease (PR+SD,
N=21). 8/28 pts (28.6%) achieved a pathologic-CR. Median
follow up was 88 months (IQR: 24-211). Median progression-
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